EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next-Generation Cancer Treatment: Photoimmunotherapy’s Promise for Unresectable Head and Neck Cancers

Laura Marinela Ailioaie iD, Constantin Ailioaie, Gerhard Litscher iD

Pharmaceutics · 29.05.2025 · 17 (6) · 716

DOI: 10.3390/pharmaceutics17060716 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.05.2025. Verfasst von Laura Marinela Ailioaie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Alexandru Ioan Cuza University, 11 Carol I Boulevard, 700506 Iasi, Romania. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional oncological therapies have contributed to reducing the global cancer burden; however, they have not achieved complete eradication, nor have they effectively prevented relapses, minimized toxicity, or preserved immune function. Recent advances, particularly the introduction of immune checkpoint inhibitors (ICIs) and CAR-T cell therapies, have markedly improved clinical outcomes and overall survival in certain cancer subtypes. Nevertheless, response rates remain suboptimal, and adverse immunological events are frequent. This review starts by highlighting the FDA-approved ICIs currently utilized in cancer immunotherapy, emphasizing those that have demonstrated clinical efficacy in recent years. The true focus of our analysis is on the latest clinical applications of near-infrared photoimmunotherapy (NIR-PIT). This emerging modality is evaluated in patients with head and neck cancers (HNC), particularly in cases that are unresectable, locally advanced, or recurrent. Finally, the review explores the current landscape and prospects of NIR-PIT, considering its potential to enhance therapeutic efficacy and extend relapse-free survival. Photoimmunotherapy is a promising, molecularly targeted option for patients with limited prognosis, offering new hope where conventional therapies fail. By synthesizing recent clinical trial data, this work highlights how NIR-PIT could bridge the translational gap between preclinical research and clinical practice. The integration of advanced technologies and interdisciplinary collaboration among researchers, clinicians, and technologists will be critical in optimizing NIR-PIT, improving its accuracy, efficacy, and safety, and ultimately advancing standards of cancer care and patient survival.

Schlagwörter

Stichwörter der Autor:innen

ASP-1929IR700NIR-PITaugmented realityepidermal growth factor receptorhead and neck squamous cell carcinomaimmune checkpoint inhibitorsimmune-related adverse eventsmixed realityvirtual reality

Autor:innen und Institutionen

  • Department of Medical Physics, Alexandru Ioan Cuza University, 11 Carol I Boulevard, 700506 Iasi, Romania.
  • Swiss University of Traditional Chinese Medicine, SWISS TCM UNI, High-Tech Acupuncture and Digital Chinese Medicine, 5330 Bad Zurzach, Switzerland.
  • President of the International Society for Medical Laser Applications (ISLA Transcontinental), German Vice President of the German-Chinese Research Foundation (DCFG) for TCM, Honorary President of the European Federatio…

ORCID-Profile: Laura Marinela Ailioaie, Gerhard Litscher

Zitieren

APA

Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2025). Next-Generation Cancer Treatment: Photoimmunotherapy’s Promise for Unresectable Head and Neck Cancers. Pharmaceutics, 17(6), 716. https://doi.org/10.3390/pharmaceutics17060716

Vancouver

Ailioaie LM, Ailioaie C, Litscher G. Next-Generation Cancer Treatment: Photoimmunotherapy’s Promise for Unresectable Head and Neck Cancers. Pharmaceutics. 2025;17(6):716. doi:10.3390/pharmaceutics17060716

BibTeX
@article{Ailioaie2025,
  author = {Ailioaie, Laura Marinela and Ailioaie, Constantin and Litscher, Gerhard},
  title = {Next-Generation Cancer Treatment: Photoimmunotherapy’s Promise for Unresectable Head and Neck Cancers},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {716},
  doi = {10.3390/pharmaceutics17060716}
}
Kostenlos starten →